WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today reported 2015 fourth-quarter and year-end financial results, highlighting strong revenue growth driven by increased Jakafi® (ruxolitinib) sales in the U.S. as well as growing ex-U.S. Jakavi® (ruxolitinib) royalties from Novartis. Additionally, Incyte provided financial guidance for 2016.
